Alan Peter Lewis

USPTO Granted Patents = 25 (Patent Applications = 30)

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 26)

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 138(Granted Patents)

Location History:

Beckenham, Kent, BR3 3BS, GB (1996)
Stevenage, GB (2010 - 2024)

Company Filing History:

12 out of 230

Glaxosmithkline Intellectual Property Development Limited

4. 1 out of 832,680

Other

patents

Years Active: 1996-2024

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12122828 - IL-7 binding proteins and their use in medical therapy (2024-10-22),

2. 11976113 - Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins (2024-05-07),

3. 11802150 - IL-7 binding proteins and their use in medical therapy (2023-10-31),

4. 11613571 - Biopharmaceutical compositions comprising antibody variants (2023-03-28),

5. 11566347 - Antibody variants (2023-01-31),

6. 11419945 - Antigen binding proteins (2022-08-23),

7. 11203632 - Antibody variants (2021-12-21),

8. 11098312 - Method of producing a recombinant protein (2021-08-24),

9. 11078287 - Binding agonist for treatment of neurological and other disorders (2021-08-03),

10. 10808040 - Modified proteins and peptides (2020-10-20),

11. 10787509 - Biopharmaceutical compositions and related methods (2020-09-29),

12. 10344088 - Antigen binding proteins (2019-07-09),

13. 10280221 - Anti-LAG-3 binding proteins (2019-05-07),

14. 10221234 - Antigen binding proteins (2019-03-05),

15. 9914781 - Binding agonist for treatment of neurological and other disorders (2018-03-13),

Title: Alan Peter Lewis: Innovative Contributions in Biopharmaceuticals

Introduction

Alan Peter Lewis, based in Stevenage, GB, is a prominent inventor with a remarkable portfolio of 24 patents. His work primarily focuses on the development of biopharmaceutical compositions, contributing significantly to medical therapies.

Latest Patents

Among his latest patents are groundbreaking innovations such as IL-7 binding proteins and their use in medical therapy. These patents involve interleukin 7 (IL-7) binding proteins, pharmaceutical compositions, and their applications in treating or preventing various diseases. Moreover, he holds patents related to biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins, aimed at treating diseases mediated by interleukin 5 (IL-5).

Career Highlights

Throughout his career, Alan has made substantial contributions while working with reputable companies like GlaxoSmithKline Intellectual Property Development Limited and Glaxo Group Limited. His innovative mindset and expertise have positioned him as a key player in the biopharmaceutical industry.

Collaborations

Collaboration has been essential to Alan's work, and he has partnered with notable colleagues, including Paul Andrew Hamblin and Tejinder Kaur Bhinder. Together, they have worked on various projects that advance the field of medical therapy.

Conclusion

Alan Peter Lewis exemplifies the innovative spirit within the biopharmaceutical sector. His numerous patents and collaborative efforts highlight his commitment to advancing medical therapies, paving the way for future breakthroughs in the treatment of diseases.

This text is generated by artificial intelligence and may not be accurate.